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INTRODUCTION
Liver cirrhosis is a major public health problem in Korea,
where it is the fourth most common cause of death (1), and
is probably linked to the high prevalence of hepatitis B virus
(HBV) infection (2) and to the culture that encourages high
alcohol consumption. According to the reports from western
countries in the 1980s (3-5), the prognosis of cirrhosis was
generally poor; the patients with compensated cirrhosis decom-
pensated at a rate of 5-10% per year, and the 5-yr survival rate
after decompensation was roughly 20%. Over the last 20 yr,
noticeable progress has been made in the management of fatal
complications, such as variceal bleeding and hepatocellular
carcinoma (6, 7), and this might have considerably altered
the survival of cirrhosis patients. Updated prognostic infor-
mation is necessary for appropriate decision-making in the
management of cirrhosis patients.
This study analyzed the prognosis of patients with cirrhosis
who were managed during the last 10 yr. The aims of this
study were 1) to evaluate survival rates and prognostic factors,
2) to investigate the pattern of development of major compli-
cations and their impact on survival, and 3) to assess the ben-
efits of two active measures designed to counter fatal compli-
cations: surveillance for hepatocellular carcinoma (HCC) and
endoscopic prophylaxis against first variceal hemorrhage.
MATERIALS AND METHODS
Selection of Patients
The study examined a retrospective cohort of 823 adult
patients with liver cirrhosis. This figure represents all the
cirrhosis patients who were followed up in our department
between September 1991 and July 1999, except those who
had HCC at first presentation (n=623) or had certain types
of cirrhosis, including primary biliary cirrhosis (n=5), Budd-
Chiari syndrome (n=4), hemochromatosis (n=1), Wilson’s
disease (n=1), and cardiac cirrhosis (n=1). In 675 patients,
liver cirrhosis was newly diagnosed during this period, and
the entry point was defined as the date of diagnosis of cirrho-
sis. For the remaining 148 patients who had been managed
for previously diagnosed cirrhosis, the entry point was defined
as the first follow-up date after September 1, 1991. Ninety-
seven patients (11.7%) dropped out during the study period,
but all of their survival data were available from the National
Death Index. For the entire cohort, the mean follow-up dura-
tion was 48 (1-94) months.
Patient Assessments
The diagnosis of liver cirrhosis was made during admission.
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The Prognosis of Liver Cirrhosis in Recent Years in Korea
The survival of a recent series of 823 cirrhosis patients who were followed up for
a mean of 48 months was analyzed. Cirrhosis was ascribed to alcohol (26%), hep-
atitis virus B (58%), hepatitis virus C (11%) or both (2%), or was cryptogenic (3%).
Features of decompensation were observed in 51% of the patients at entry, and
newly developed in 44% of compensated patients within 5 yr. The 5-yr survival
after decompensation was 25%. The leading causes of death were liver failure
(53%), hepatocellular carcinoma (HCC, 23%), and variceal bleeding (10%). Early
detection of HCC significantly improved the survival of cirrhosis patients. Biannual
ultrasonography increased the detection rate of small HCC. Mortality of variceal
hemorrhage was much lower in patients with Child-Pugh scores from 5 to 8 than
in those with scores above 8 (5% vs. 52%). Endoscopic prophylaxis significantly
decreased the incidence of first variceal hemorrhage, but the effect was insufficient
to improve the rate of survival. Mortality of first spontaneous bacterial peritonitis
was 18%. These data suggest that the mortality of major complications of liver
cirrhosis has considerably decreased during the last two decades, while there
was no remarkable improvement in long-term survival. More efficient management
of etiologic factors would be required.
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At admission, all the patients gave a full history, and under-
went a complete physical and laboratory examinations includ-
ing routine blood biochemistry, prothrombin time, blood cell
count, and viral markers. Furthermore, upper gastrointestinal
endoscopy, abdominal ultrasonography, and if needed, com-
puterized tomography (CT) were performed. The diagnosis
was biopsy-proven in 450 patients by using the histological
criteria, proposed by Scheuer (8). In the remaining 373 pa-
tients, the recognition of ascites and an irregular liver surface
on imaging studies, in addition to esophageal varices on en-
doscopy, was considered sufficient for the diagnosis.
HBV infection was recognized by identifying hepatitis B
surface antigen (HBsAg) in the serum, and was further eval-
uated by checking hepatitis B e antigen (HBeAg), anti-HBe
antibody, and HBV DNA in serum. Hepatitis C virus (HCV)
infection was recognized by detecting anti-HCV antibody in
serum, and by confirming HCV RNA in serum with the poly-
merase chain reaction. The etiology of liver cirrhosis was clas-
sified as follows: HBV- or HCV-related cirrhosis was diagnosed
in patients seropositive for HBsAg or anti-HCV, respectively.
Alcoholic cirrhosis was diagnosed in patients with a habit of
alcohol abuse who were seronegative for HBsAg and anti-
HCV. Alcohol abuse was defined as the consumption of more
than 80 g of alcohol per day for more than 5 yr. Cryptogenic
cirrhosis was diagnosed in nonalcoholic patients who were
seronegative for viral markers.
Decompensation was defined as the presence of ascites, jaun-
dice, encephalopathy, or variceal bleeding. Jaundice was de-
fined as serum bilirubin levels >2 mg/dL. Ascites was detected
by ultrasonography and confirmed by paracentesis. Sponta-
neous bacterial peritonitis (SBP) was diagnosed according to
Runyon (9). Encephalopathy was recognized using standard
criteria (10). The prothrombin time was expressed as the activi-
ty percentage. The degree of overall hepatic decompensation
was assessed using the Child-Turcotte-Pugh score (11). Eso-
phageal varices were described using Japanese guidelines with
some modifications (12). In this study, varices were divided
into two size categories: small (F1) or large (F2 or F3). Simi-
larly, the red color (RC) sign was also categorized into two
levels: positive or negative. When death occurred within 6
weeks of gastrointestinal bleeding, it was regarded as a bleed-
ing-related death (13). HCC was diagnosed by ultrasound-
or CT-guided biopsy, or by the combination of typical angio-
graphic findings with an alpha-fetoprotein level over 400
ng/mL. Small HCC was defined as a single tumor <5 cm, or
2-3 tumors <3 cm without invasion of major veins larger than
sub-segmental branches. These criteria are the same one ap-
plied to define the early stage HCC in BCLC staging scheme
(14). The tumors exceeding these limits were regarded as ad-
vanced HCC. Cholelithiasis was detected by ultrasonography.
Follow-up was usually conducted in the outpatient clinic
at 3-month intervals, but was more frequent for those with
decompensated cirrhosis. On each occasion, the patients under-
went physical and laboratory examinations to assess possible
alterations in hepatic function and the development of com-
plications. For early detection of HCC, the serum alpha-feto-
protein level and ultrasonography were checked in every 3 and
6 months, respectively, as a rule.
Treatments
Ascites, SBP, and encephalopathy were treated following
textbook guidelines. If a subject had a sign of gastrointestinal
bleeding, he or she was hospitalized immediately for emergen-
cy endoscopy and adequate hemostatic treatment. For variceal
bleeding, the patients underwent an emergency endoscopic
band ligation or sclerotherapy, or supportive management
using balloon tamponade or somatostatin or vasopressin fol-
lowed by elective endoscopic treatment. Endoscopic treatment
aimed to eradicate the varices, and was repeated, if needed.
Once HCC was diagnosed, hepatic resection was recommend-
ed for the patients with operable tumors and compensated
cirrhosis. For inoperable HCC, non-surgical treatments were
considered, including transarterial oily chemo-embolization,
local ablative therapies involving percutaneous ethanol injec-
tion or radiofrequency wave ablation, or combined modalities.
Local ablation was generally used for small HCC.
Data Analysis
The cumulative survival rates and cumulative incidences of
major complications were computed using the Kaplan-Meier
method (15). The prognostic role of various clinical parame-
ters for death and the development of HCC or variceal hem-
orrhage was assessed using univariate and multivariate ana-
lyses. In the univariate analysis, Kaplan-Meier curves were
compared using the log rank test for each variable. Multivari-
ate analyses were conducted using Cox’s regression model (16)
with the variables for which p<0.1 in the univariate analyses.
The variables yielding continuous values were categorized
into two levels in the univariate analysis using their median
value, while they were introduced intact as continuous values
in the multivariate analysis. Chi-square or Fisher’s exact tests
were used to compare ratios, and ANOVA or Student’s t-test
to compare averages. All the analyses were performed using
the program SAS. The significance level was set at 0.05, and
two-tailed tests were used. 
RESULTS
Initial Characteristics of the Patients 
The initial characteristics of the patients at entry are sum-
marized in Table 1. In the entire series, 603 (73%) of 823
patients were men. The mean age was 50 yr (range: 16-82).
Cirrhosis was compensated in 401 (49%) patients and decom-
pensated in 422 (51%). Fifty patients in the compensatedPrognosis of Liver Cirrhosis 835
group at entry had a previous history of decompensation. In
the decompensated group at entry, ascites was found in 281
(67%), jaundice in 207 (49%), variceal bleeding in 119 (28%),
and encephalopathy in 45 (11%). Esophageal varices were
found in 582 (71%). The main comorbid conditions were
diabetes mellitus in 127 (15%), cholelithiasis in 39 (5%), and
hypertension in 32 (4%).
Cirrhosis was related to HBV in 481 (58%) patients, HCV
in 89 (11%), and HBV and HCV co-infection in 14 (2%);
alcohol abuse was recognized in 346 (42%) patients, including
211 (26%) with alcoholic cirrhosis; cirrhosis was cryptogenic
in 28 (3%). The patients with alcoholic cirrhosis were predom-
inantly male, while most of the patients with cryptogenic cir-
rhosis were female as shown in Table 2. At the time of diag-
nosis of cirrhosis, the mean age of patients was significantly
different (p<0.001) depending on the etiologies of cirrhosis;
lowest in HBV-related cirrhosis and highest in HCV-related
cirrhosis. Also, there were significant differences (p<0.001)
in the incidence of decompensation or esophageal varices; high-
est in the patients with alcoholic cirrhosis and lowest in those
with HCV-related cirrhosis (Table 2).
Causes of Deaths
A total of 362 patients died during the study period, and
the causes of death were identified from 310. Liver failure
accounted for 165 deaths (53%), progression of HCC for 73
(23%), variceal bleeding for 28 (10%), infection for 13 (5%),
Factors
No. of
Patients
5-yr
Survival
p-value Factors
No. of
Patients
5-yr
Survival
p-value
Gender
Male 603 57% 0.06
Female 220 63%
Age (yr)
≤50 427 65% <0.0001
≥51 396 50%
Cause of cirrhosis 
Alcohol 211 59%
HBV*-related
HBV 376 59%
HBV & Alcohol 105 47% 0.06
HCV
� -related
HCV 65 65%
HCV & Alcohol 24 55%
HBV & HCV-related 14 62%
Cryptogenic 28 69%
Varix
Absent 241 78% <0.0001
Present 582 50%
Albumin (g/dL)
≤3.6 413 43% <0.0001
>3.6 410 74%
Bilirubin (mg/dL)
≤1.4 383 70% <0.0001
>1.4 440 48%
Prothrombin (%)
≤80 412 47% <0.0001
>80 411 70%
Ascites
Absent 540 71% <0.0001
Controllable 200 44%
Intractable 83 7%
Encephalopathy
Absent 778 60% <0.0001
Present 45 22%
Platelets (10
3/L )
≤920 407 50% <0.0001
>920 416 66%
AST
�(IU/L)
≤67 415 63% 0.001
>67 408 53%
ALP
� (IU/L) 
≤81 417 67% <0.0001
>81 406 50%
GGT
‖ (IU/L)
≤62 414 62% 0.19
>62 409 55%
BUN
¶ (mg/dL)
≤13 477 61% 0.12
>13 346 55%
Creatinine (mg/dL) 
≤0.8 572 59% 0.70
>0.8 251 56%
Diabetes mellitus
Present 127 46% 0.09
Absent 696 60%
Hypertension
Present 32 50% 0.71
Absent 791 59%
Gall bladder stone
Present 39 63% 0.75
Absent 784 58%
Table 1. Initial characteristics of patients in the series and the results of the univariate analysis of survival
*hepatitis virus B, 
� hepatitis virus C, 
� aspartate aminotransferase, 
�alkaline phosphatase, 
‖gamma glutamyl transpeptidase, 
¶blood urea nitrogen.
*Coinfection with HBV and HCV.
Alcoholic HBV HCV B&C* Cryptogenic
Number of patients 211 481 89 14 28
Age (Mean±SD) 52±10 46±10 60±95 1 ±10 57±11
Male patients (%) 200 (95) 331 (69) 53 (60) 12 (86) 7 (25)
Decompensated  161 (76) 250 (52) 34 (38) 9 (64) 18 (64)
cirrhosis (%)
Esophageal  182 (86) 311 (65) 53 (60) 8 (57) 19 (68)
varices (%)
Table 2. Patient characteristics at diagnosis of cirrhosis accord-
ing to etiology 836 Y.S. Kim, S.H. Um, H.S. Ryu, et al.
other digestive bleeding for 6 (2%), other malignancy for 4
(1%), and other causes for 21 (7%). Variceal bleeding was a
terminal event in 12 of the patients who died of advanced
HCC. Among the patients who died of liver failure, 55 (33%)
and 29 (18%) were combined with SBP or hepatorenal syn-
drome, respectively. In patients with alcoholic cirrhosis, va-
riceal bleeding was a more frequent cause of death than HCC
(18% vs. 8%).
Survival and Prognostic Indicators at Entry
The cumulative survival rates in the whole series were 94,
76, 58, and 46% at 1, 3, 5, and 7 yr after inclusion, respective-
ly. Survival was much better in patients with compensated
cirrhosis than in the decompensated group, with respective
5-yr survival rates of 74% and 43%. The Child-Turcotte-Pugh
scoring system allowed a more detailed prediction of survival
depending on the severity of decompensation (Fig. 1). In this
series, the 1-yr survival rate was 96% for patients with a Child-
Turcotte-Pugh score of 6 to 8, and 40% for those with scores
above 11.
In the univariate analysis of the entire series (Table 1), 13
of 18 variables at entry were linked to survival with p<0.1.
Ten of them had independent (p<0.05) relationships with
survival in the multivariate analysis (Table 3). The rate of sur-
vival was reduced for patients with male gender, older age,
varix, ascites, prolonged prothrombin time (PT), lower platelet
count, low serum albumin levels, and high levels of serum
bilirubin or alkaline phosphatase (ALP). The patients with
alcoholic cirrhosis had significantly better survival rate than
those with HBV-related cirrhosis. In the multivariate analy-
sis for subgroups, varix and ALP had a prognostic significance
specifically for compensated cirrhosis, while bilirubin and PT
were significant for decompensated cirrhosis.
The Status of Etiologic Factors during Follow-up and
Their Impact on Survival
Sixty-one (28%) of 211 patients with alcoholic cirrhosis
and 75 (56%) of 135 alcohol abusers with viral cirrhosis per-
manently stopped drinking during the study period. They
had a significantly better survival than those who continued
to abuse alcohol (Table 4). In the subgroup analysis based on
the Child-Turcotte-Pugh score, however, the benefit of absti-
nence was recognized only for patients with a fairly good hep-
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Fig. 1. Survival probability (Kaplan-Meier plot) in four subgroups
based on the Child-Turcotte-Pugh scores. The numbers at the bot-
tom of the figure are the numbers of patients at risk.
Variables
Hazard ratio 
(95% confidence interval)
p value
Gender (female/male) 0.687 (0.527-0.896) 0.0056 
Age (yr) 1.037 (1.026-1.049) <0.0001
Varices (present/ absent) 1.552 (1.147-2.102) 0.0045
Albumin (g/dL) 0.581 (0.461-0.731) <0.0001
Bilirubin (mg/dL) 1.166 (1.076-1.264) 0.0002
PT (%) 0.990 (0.983-0.998) 0.0116
Ascites (intractable/ absent) 3.443 (2.517-4.710) <0.0001
Platelet count (10
3/ L) 0.962 (0.937-0.988) 0.0045
ALP (IU/L) 1.003 (1.001-1.004) 0.0006
Etiology of cirrhosis 1.608 (1.214-2.130) 0.0009
(HBV-related/alcoholic)
Table 3. Prognostic factors for survival at entry in the multivariate
analysis for the entire series using the Cox regression model 
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Fig. 2. Survival probability (Kaplan-Meier plot) in alcoholic patients
who continued to abuse or stopped abusing alcohol. The survival
benefit of abstinence was significant only in patients with Child-
Turcotte-Pugh scores of 5 to 8 at entry.
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atic reserve, but not in those with advanced decompensation
features, as shown in Fig. 2.
Of the 495 patients with HBsAg, 143 (29%) were seroneg-
ative for both HBeAg and HBV DNA at entry, but 12 (8%)
of them reverted to seropositive state thereafter. By contrast,
27 (8%) of 352 patients who had been seropositive for HBeAg
or HBV DNA at entry became seronegative for both markers
during follow-up. Overall, viral replication was suppressed in
a total of 158 (32%) patients during the study period, and
they showed a significantly improved survival rate compared
to those with active viral replication (Table 4). However, this
benefit was also significant only for the patients with compen-
sated cirrhosis at entry (Fig. 3).
Development of Decompensation
Of the 351 patients who had never experienced decompen-
sation at entry, 140 became decompensated during follow-up,
with cumulative incidences of 13% and 44% at 1 and 5 yr
after inclusion, respectively. The first sign of decompensation
was ascites in 110 (79%), jaundice in 81 (58%), encephalopa-
thy in 20 (14%), and variceal bleeding in 19 (14%). The 5-
yr survival rate from entry was 97% in patients who did not
develop decompensation, but 41% in those who decompen-
sated. The survival rates after the initial episode of decompen-
sation were 68% at 1 yr and 25% at 5 yr. Of note, the 5-yr
survival after the appearance of ascites was 16%.
Development of Hepatocellular Carcinoma
One hundred and eighteen patients developed HCC during
follow-up, with a cumulative incidence of 3% at 1 yr and 19%
at 5 yr after inclusion. HBV- or HCV-related cirrhosis was
more frequently complicated by HCC than alcoholic cirrhosis,
with the 5-yr cumulative incidence in each group being 24%,
28% and 5%, respectively. In addition, male gender, older
age, esophageal varices, and high serum alkaline phosphatase
level were independently associated (p<0.05) with a higher
risk of HCC (Table 5).
At the initial diagnosis of HCC, 69 (59%) patients had
small HCC, while 80 (68%) patients were in a decompensated
state. Hepatic resection was performed in 7 (6%) patients, local
ablation combined with chemo-embolization in 36 (31%),
chemo-embolization alone in 37 (31%), and conservative
management in 35 (30%); 3 patients dropped out after the
diagnosis. Active treatment of HCC was attempted in 80%
of the cases with small HCC and in only 55% of advanced
Variables
Hazard ratio
(95% confidence interval)
p value
Gender (female/male) 0.444 (0.278-0.712) 0.0007
Age (yr) 1.061 (1.040-1.082) <0.0001
Etiology of cirrhosis 
(HBV-related/alcoholic) 11.598 (5.322-25.274) <0.0001
(HCV-related/alcoholic) 7.248 (3.004-17.486) <0.0001
Varices (present/absent) 1.823 (1.164-2.855) 0.0087
ALP (IU/L) 1.005 (1.002-1.008) 0.0018
Table 5. Risk factors for HCC using the Cox regression model
P
r
o
b
a
b
i
l
i
t
y
 
(
%
)
0 1 2 2 43 64 8 6 07 28 49 6
Months
100
50
0
100
50
0
100
50
0
Child-Push Score 5
I: HBeAg (-) and HBV DNA (-)
II: HBeAg (+) or HBV DNA (+)
Child-Push Score 6-8
Child-Push Score ≥9
Fig. 3. Survival probability (Kaplan-Meier plot) in patients with
HBV-related cirrhosis according to the HBeAg status and HBV
DNA in the serum during follow-up. A significant difference in sur-
vival was observed between groups I and II only for the patients
with a Child-Turcotte-Pugh score of 5 at entry.
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II (n=63)
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p=0.055
p=0.513
Events
No. of
patients 
Survival
3-yr 5-yr
p value
Alcohol abuse
Stop 136 82% 71% <0.0001
Continue 210 69% 48%
Clearance of HBeAg
and HBV DNA 
Absent 337 71% 52% 0.0002
Present 158 83% 66%
Hepatocellular carcinoma
Absent 705 78% 67% <0.0001
Small* 69 77% 37%
Advanced 49 57% 22%
Upper GI bleeding
Absent 687 79% 64% <0.0001
Present 136 64% 40% 
SBP
Absent 674 82% 68% <0.0001  
Present 149 50% 26%
Table 4. Univariate analysis of survival in relation to important clin-
ical events during follow-up
*Hepatocellular carcinoma consisting of a single nodule <5 cm or 2-3
nodules <3 cm without invasion of major veins.838 Y.S. Kim, S.H. Um, H.S. Ryu, et al.
cases. The life expectancy following entry was longer in pa-
tients in whom HCC was detected at the stage of small HCC
than in those with HCC detected at advanced stage, although
both groups had shorter survival times than those who did
not develop HCC (Table 4, Fig. 4).
Development of Upper Gastrointestinal Bleeding
During follow-up, 163 upper gastrointestinal (GI) bleeds
developed in 136 patients. The origins of the bleeding were
identified in 157 cases by endoscopy: esophago-gastric varices
in 138 (87.9%), gastric ulcer in 13 (8.3%), hemorrhagic gas-
tropathy in 2 (1.3%), duodenal ulcer in 2 (1.3%), esophageal
ulcer in 1 (0.6%), and esophagitis in 1 (0.6%).
The patients who developed upper GI hemorrhages during
follow-up had a lower survival rate than those without bleed-
ing (Table 4). The overall mortality of variceal bleeding was
29% (40/138), and was almost the same in initial (25/87) and
recurrent (15/51) episodes. By contrast, the mortality from
non-variceal upper GI bleeding was 11% (2/19). The cumu-
lative survival rate after the first variceal bleed was 71% at 6
weeks, 58% at 1 yr, and 20% at 5 yr, but there were signifi-
cant differences (p<0.0001) depending on the severity of hep-
atic decompensation at the time of bleeding (Fig. 5). For exam-
ple, the 6-week survival rate was 95% (37/39) in patients with
Child-Turcotte-Pugh scores from 5 to 8, but 52% (25/48) in
those with scores above 8. The cumulative incidence of recur-
rent variceal bleeding was 11% at 6 weeks, 25% at 1 yr, and
54% at 5 yr.
Development of Spontaneous Bacterial Peritonitis
(SBP)
At least one episode of SBP occurred in 149 (30%) of the
502 patients with ascites during the investigation. The cumu-
lative incidence of the first episode of SBP was 27% at 1 yr
and 44% at 5 yr after developing ascites in 194 patients who
experienced ascites for the first time during follow-up. At first
presentation of SBP, most patients had advanced liver dysfunc-
tion, and their mean (±SD) Child-Turcotte-Pugh score was
10.5±2.3. As expected, the patients who developed SBP
during follow-up had reduced survival from entry (Table 4).
Twenty-seven (18%) of 146 patients died shortly after their
first episode of SBP, while still in hospital. Of the 119 patients
discharged alive, 58 (50%) developed recurrent SBP with a
cumulative incidence of 44% at 1 yr and 68% at 5 yr. The
survival rate after first SBP was 46% at 1 yr and 10% at 5 yr.
The Effectiveness of Surveillance Programs for 
Hepatocellular Carcinoma
We evaluated the effectiveness of our surveillance program
for HCC, which involves regular ultrasonography and mea-
surement of serum alpha-fetoprotein levels. Of 118 patients
with HCC in this series, the most recent ultrasound examina-
tion just before the diagnosis of HCC was 6 months or less
in 35 patients (group I), 7 to 12 months in 46 patients (group
II), and more than 1 yr in 37 patients (group III).
The frequency of small HCC in groups I or II was higher
than in group III (69% or 63 vs. 43%, p<0.05). However,
life expectancy after entry was similar in all three groups, as
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indicated by the 5-yr survival rates, which were 30%, 33%,
and 29% in groups I, II, and III, respectively. Although the
prognostic factors at baseline were adjusted in the multivari-
ate analysis, no significant benefit in survival was recognized.
The Benefit of Endoscopic Prophylaxis against First
Variceal Bleed
We assessed the effect of endoscopic prophylaxis against
first variceal bleeds for the patients who had large esophageal
varices (Japanese classification F2 or F3) without coincident
HCC or severe decompensated cirrhosis (Child-Turcotte-Pugh
scores over 12). The effect of beta-blockers was not evaluated
because there were too few cases and the schedule of medica-
tions was not consistent. 
Throughout the study period, 441 patients were found to
have large esophageal varices (Japanese classification F2 or F3).
One hundred and eighty-seven of them, however, had previous
or ongoing variceal bleedings at the time of diagnosis; 9 had
coincident HCC; 8 presented the features of severe decompen-
sation. Among the remaining 237 patients who met the above
inclusion criteria, 75 underwent endoscopic prophylaxis (band-
ligation in 50, sclerotherapy in 9, and a combination of the
two methods in 16), 29 were given oral propranolol, and 133
were given no prophylaxis. At baseline, the endoscopy pro-
phylaxis group had a higher prevalence of red color sign (67%
vs. 44%, p<0.01), and had a slightly lower mean (±SD) value
of Child-Turcotte-Pugh score (6.5±1.7 vs. 7.1±1.8, p<0.05)
compared with the no-prophylaxis group.
The cumulative incidence of first variceal bleed after the
diagnosis of large varices was significantly lower in the pro-
phylaxis group than in the no-prophylaxis group, with 3-yr
incidences of 18% and 42%, respectively (Fig. 6). This pre-
ventive effect still remained significant in multivariate ana-
lysis, which adjusted several potential risk factors of variceal
hemorrhage at base line that had shown p<0.1 in univariate
analysis, such as red color sign, serum bilirubin level, gender,
aspartate aminotransferase, and gammaglutamyl transpepti-
dase (Table 6). 
However, there was no significant difference in the cumu-
lative survival rates between the prophylaxis and no-prophy-
laxis groups, with 3-yr survival rates of 68% and 58%, respec-
tively. Furthermore, no survival benefit was observed in the
univariate analysis considering the Child-Turcotte-Pugh scores
at baseline or in the multivariate analysis adjusting the pro-
gnostic factors at baseline.
DISCUSSION
In the present study, the main causes of liver cirrhosis were
HBV, HCV, and alcohol, which accounted for the origin of ci-
rrhosis in 60%, 13%, and 26% of the whole patients, respecti-
vely. The predominant role of HBV in viral cirrhosis reflects the
high prevalence of chronic HBV infection in this country (2).
Depending on the etiologies of cirrhosis some clinical fea-
tures were distinctive. The patients with alcoholic cirrhosis
were predominantly male (95%), presumably this being relat-
ed with the cultural background in alcohol ingestion, and
most of them (75%) showed decompensation features at first
presentation, suggesting chronic alcoholics usually keep drink-
ing without insight until decompensated. HBV-related cirrho-
sis was diagnosed in mid-forties on average, relatively earlier
than in other types of cirrhosis. This presumably may be asso-
ciated with the vertical transmission of HBV, the main route
of HBV infection in this country, which elicits chronic hep-
atitis from earlier ages. In contrast, HCV-related cirrhosis was
detected at the mean age of 60, and was compensated in 60%
of cases. Compared with alcoholic cirrhosis, viral cirrhosis was
complicated by HCC approximately 5-fold more in frequency.
As a result, HCC was responsible for about one third of total
deaths in viral cirrhosis, whereas only 8% of all deaths in alco-
holic cirrhosis. Instead, variceal bleeding was a more dominant
cause of death in alcoholic cirrhosis. 
As expected from the causes of death in the cirrhosis patients,
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Fig. 6. Cumulative probability (Kaplan-Meier plot) of developing a
first variceal hemorrhage in two subgroups of patients with large
esophageal varices: those who did and did not receive endoscopic
prophylaxis. The numbers at the bottom of the figure are the num-
bers of patients at risk. 
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2
Variables
Hazard ratio 
(95% confidence interval)
p value
Bilirubin (mg/dL) 1.371 (1.090-1.725) 0.007
Red color sign 4.683 (2.516-8.718) 0.000
(present/absent)
Endoscopic prophylaxis 0.286 (0.151-0.542) 0.000
(present/absent)
Table 6. Risk factors for first variceal hemorrhage in patients with
large esophageal varices using the Cox regression model (n=
208)840 Y.S. Kim, S.H. Um, H.S. Ryu, et al.
the clinical variables representing the severity of hepatic failure
or portal hypertension, including the five variables used in the
Child-Turcotte-Pugh system, esophageal varices, and throm-
bocytopenia, are reported as the key prognostic indicators of
liver cirrhosis (4, 5, 11, 17, 18), and their importance was
reconfirmed in the present study. Also, the variables such as
age, gender, and serum alkaline phosphatase level had prog-
nostic significance, as previously reported (4, 5, 17, 18). Of
interest, these three factors had a significant correlation with
the risk of developing HCC as well.
It is well known that efficient management of etiologic
factors is closely correlated with survival in cirrhosis patients
(3, 4, 17-20). In this study, we were able to confirm that the
prognosis was far better in the patients who stopped drinking
during follow-up than in those who continued to drink, and
the patients with inactive HBV replication had a higher sur-
vival rate than those with consistent viral replication. Further-
more, we demonstrated that these benefits were seen only in
patients with compensated or mildly decompensated cirrhosis
in the subgroup analysis. This emphasizes that the control of
etiologic factors must be attempted at an earliest stage of cir-
rhosis, if possible, to improve the rate of survival substantially.
In addition, the better prognosis of alcoholic cirrhosis in our
study compared with HBV-related cirrhosis might be explain-
ed by the differing intractability of etiologic factors, i.e., 28%
of the patients with alcoholic cirrhosis succeeded in abstain-
ing from alcohol after entry, while only 8% of the patients
with HBV-related cirrhosis showed HBeAg seroconversion
during follow-up. Indeed, we could not find any significant
difference in survival between alcoholic and HBV-related cir-
rhosis when the patients who stopped drinking were excluded.
In this study, 44% of the patients with compensated cirrho-
sis developed decompensation signs within 5 yr after entry,
and the 5-yr survival rate after decompensation was 25%.
These data are similar to the figures reported in the 1980s
(3-5); therefore, it is difficult to say that there has been a sub-
stantial improvement in the long-term survival of cirrhosis
patients during the last 20 yr. Although the 5-yr survival rate
in patients who had been decompensated at entry appears
higher in the present series as compared with previous results
(40% vs. 16-21%), it can be noted that our series included
a relatively lower percentage of patients with ascites and no
patients with HCC at entry.
However, the short-term prognosis of some major compli-
cations appears to have remarkably improved. For example,
in this study, which took vigorous endoscopic measures to
prevent variceal rebleeding, the rebleeding rate after a first
variceal hemorrhage was 11% at 6 weeks and 25% at 1 yr.
These values are much lower than the figures of 20-50% at
6 weeks and 47-84% at 1 yr in untreated cases in earlier stud-
ies (6). Correspondingly, the 6-week mortality after variceal
hemorrhage was decreased to 29% (22% when terminal HCC
patients were excluded) in our study, and to 5% in patients
with Child-Turcotte-Pugh scores below 9, as compared to
33-71% in prior studies (6, 21). Similarly, the hospital mortal-
ity of SBP in this study was reduced to 18% compared with
40-50% in previous reports (22-24).
After considering tumor stage and functional hepatic reserve,
a mere 6% of the patients with HCC underwent partial hep-
atectomy in this study, and another 62% were treated non-sur-
gically. It is now evident that the development of non-surgi-
cal modalities has enlarged the range of therapeutic indications
for HCC patients, especially for cases that are inoperable due
to impaired liver function or multiple lesions. Particularly,
patients with small HCC had more opportunities for treatment
than those with advanced HCC (80% vs. 55%). In concert
with these findings, it is noteworthy that the patients with
small HCC had a significantly longer life expectancy from
entry, as well as after the diagnosis of HCC, than those with
advanced HCC. This indicates that early detection of HCC
can lead to a genuine survival benefit in cirrhosis patients, and
provides good grounds for regular surveillance for the early
detection of HCC. As far as we know, this study will be the
first to demonstrate that early detection of HCC can improve
the survival of cirrhosis patients beyond the lead-time bias
(25). Unfortunately, however, biannual ultrasonography in
this study failed to achieve a significant improvement in sur-
vival, although it increased the detection rate of small HCC
in the screened group by more than 20%. This is most like-
ly because about 30% of cases of small HCC were still over-
looked on ultrasound examination, probably due to limitations
of sonography and the inexpertness of the examiners. There-
fore, in order to improve the detection rate of small HCC in
cirrhosis patients, it is necessary to introduce complementary
imaging modalities with higher resolution and to develop
highly sensitive tumor markers.
In this study, endoscopic prophylaxis for a first variceal
bleed significantly reduced the bleeding rate, in spite of the
higher incidence of the RC sign in the prophylaxis group at
baseline. However, we did not find a significant improvement
in survival, although there were fewer signs of decompensa-
tion in the prophylaxis group at baseline. This concurs with
previous studies (26-29). Of course, the possibility of type II
error still exists in our study, since the prophylaxis group had
a higher survival rate than the non-prophylaxis group by 10%
at 3 yr, although this was not significant. Nonetheless, the
expected survival benefit of endoscopic prophylaxis does not
seem very high, even if it has a statistical significance. This
low potential benefit might be ascribed to the reduced bleed-
ing-related mortality that has resulted from the progress in
the management of variceal hemorrhage, and the development
of means to prevent rebleeding, especially in patients with
an otherwise good prognosis. Therefore, for endoscopic pro-
phylaxis against a first variceal hemorrhage, a more discreet
approach might be required that considers cost-effectiveness,
and a stricter selection of target patients is desirable, since the
3-yr bleeding rate was only 42% in patients with large varices
in this study.Prognosis of Liver Cirrhosis 841
In summary, this study provided a wide range of updated
prognostic information that will be helpful for the appropriate
management of cirrhosis patients. We found that 1) effective
control of causative agents increased life expectancy in patients
with compensated or mildly decompensated cirrhosis; 2) early
detection of HCC led to a genuine survival benefit; 3) the
short-term prognosis of some major complications, such as
variceal hemorrhage and SBP, has considerably improved over
the last two decades, while there was no remarkable improve-
ment in the long-term survival of cirrhosis patients; and 4)
biannual ultrasonography increased the detection rate of small
HCC and endoscopic prophylaxis decreased the incidence of
first variceal hemorrhage without improving survival. These
results suggest that more efficient management of etiologic
factors and complications is necessary to improve the prognosis
of compensated or mildly decompensated cirrhosis. In severely
decompensated cirrhosis, liver transplantation might be the
only therapeutic option that alters the outcome.
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